This is a working overview of Mass spectrometry, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-31 and is reviewed periodically as new material appears.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Digital artery pressures are measured in the arteries of the fingers before and after the hands have been cooled. A decrease of at least 15 mmHg is diagnostic (positive). Doppler ultrasound to assess blood flow Full blood count may reveal a normocytic anaemia suggesting the anaemia of chronic disease or kidney failure. Blood test for urea and electrolytes may reveal kidney impairment. Thyroid function tests may reveal hypothyroidism. Tests for rheumatoid factor, erythrocyte sedimentation rate, C-reactive protein, and autoantibody screening may reveal specific causative illnesses or an inflammatory process. Anti-centromere antibodies are common in limited systemic sclerosis (CREST syndrome). Nail fold vasculature (capillaroscopy) can be examined under a microscope. To aid in the diagnosis of Raynaud's phenomenon, multiple sets of diagnostic criteria have been proposed. Table 1 below provides a summary of these various diagnostic criteria. Recently, International Consensus Criteria were developed for the diagnosis of primary Raynaud's phenomenon by a panel of experts in the fields of rheumatology and dermatology.
Guzmán G. (1983). The genus Psilocybe: A Systematic Revision of the Known Species Including the History, Distribution and Chemistry of the Hallucinogenic Species. Nova Hedwigia Beihefte. Vol. 74. Berlin: J. Cramer. ISBN 978-3-7682-5474-8. Bresinsky A, Besl H (1989). A Colour Atlas of Poisonous Fungi: a Handbook for Pharmacists, Doctors, and Biologists. London, UK: Manson Publishing Ltd. ISBN 978-0-7234-1576-3. Stamets P. (1996). Psilocybin Mushrooms of the World: An Identification Guide. Berkeley, California: Ten Speed Press. ISBN 978-0-89815-839-7. Gartz J. (1997). Magic Mushrooms Around the World. Los Angeles, California: LIS Publications. ISBN 978-0-9653399-0-2.
== Unconfirmed (16) == Evidence for the existence of the following molecules has been reported in the scientific literature, but the detections either are described as tentative by the authors, or have been challenged by other researchers. They await independent confirmation.
Helene Langevin is an American medical scientist who served as the Director of the National Center for Complementary and Integrative Health (NCCIH) at the National Institutes of Health (NIH) between November 2018 and November 2025. She was a professor in the University of Vermont College of Medicine's Department of Neurological Sciences. She is best known for characterizing certain cellular and mechanical effects of acupuncture. She was also a Professor in Residence of Medicine at Harvard Medical School, Brigham and Women's Hospital. Prior to working at NIH, Langevin was the Director of the Osher Center for Integrative Medicine, jointly owned by Brigham and Women's Hospital and Harvard Medical School. Langevin was the principal investigator of studies funded by the National Institutes of Health. The Boston Globe describes her as a "celebrity" in the world of acupuncture.
Sources: en.wikipedia.org
== Literature == Michael Bliss: Theodore Ryder: The Last Living Link to the Discovery of Insulin. In: Practical Diabetes International. 12(4)/1995. John Wiley & Sons, S. 187–188, ISSN 1357-8170 Katharine Martyn: Teddy Ryder's Scrapbook. In: The Halcyon. The Newsletter of the Friends of the Thomas Fisher Library. Ausgabe 24, November 1999; online under Teddy Ryder's Scrapbook
== Bibliography == Gasnault, François (2007). Sur les traces de vos ancêtres à Paris [On the trail of your ancestors in Paris] (in French). Paris: Archives de Paris. Abensur-Hazan, Laurence (2011). Recherche ses ancêtres à Paris [Search for ancestors in Paris] (in French). Paris: Autrement généalogies. Barroux, Maurice (1898). Les sources de l'ancien état civil parisien [Parisian civil registry sources] (in French). Paris: Honoré Champion Éditeur. Archived from the original on October 31, 2020. de Blaignerie, Henri; Dangin, Édouard (2009). Paris incendié pendant la Commune - 1871 [Paris set on fire during the Commune - 1871] (in French). Paris: Les Éditions du Mécène. de Brossard, Yolande (1965). Musiciens de Paris 1535-1792, actes d'état civil d'après le fichier Laborde de la Bibliothèque nationale [Musiciens de Paris 1535-1792, civil status records from the Bibliothèque nationale's Laborde file] (in French). Paris: Éditions Picard. de Chastellux, Henri Paul César (1875). Notes prises aux archives de l'état-civil de Paris, avenue Victoria, 4, brûlées le 24 mai 1871 [Notes taken from the archives of the Paris registry office, avenue Victoria, 4, burnt on May 24, 1871] (in French). Paris: Dumoulin. Delsalle, Paul (2009). Histoires de familles, les registres paroissiaux et d'état civil, du Moyen Âge à nos jours, démographie et généalogie [Family histories, parish and civil registers, from the Middle Ages to the present day, demography and genealogy] (in French). Besançon: Presses universitaires de Franche-Comté. Fierro, Alfred (1996).
== Regulation of sulfur assimilation == Sulfur assimilation is highly regulated and influenced by both external environmental factors and internal metabolic feedback pathways, in order to maintain sulfur homeostasis. Under sulfur-deficient conditions, plants modify their internal pathways to enhance sulfur uptake. In plants, a key regulator is the transcription factor SLIM1 (Sulfur Limitation 1), which functions in activating genes involved in sulfur transport like SULTR1;2 (a high-affinity transporter) and those involved in sulfur assimilation like ATP sulfurylase and APS reductase. The post-transcriptional regulation of these genes are done via a microRNA called miR395. When sulfur uptake is sufficient and is no longer limited, this microRNA targets the SULTR2;1(a low-affinity transporter) and degrades/inhibits its translation. Besides the transcriptional regulation of sulfur assimilation, there also lies post-translational mechanisms that control this process. This includes feedback inhibition by the accumulation of end products such as glutathione and cysteine, as well as regulation of the enzyme APS reductase which is activated or inhibited by the redox state of the cell. In fungi, specifically the Aspergillus fumigatus, sulfur assimilation is managed by the transcription factor MetR. This transcription factor functions similarly to SLIM1, in which under sulfur-limiting conditions it activates genes responsible for sulfur uptake. MetR also plays a key role in protecting the fungus's virulence against the host-immune system.
Sources: en.wikipedia.org
In 1264, after Sanlúcar de Barrameda was seized from the Moors by King Alfonso X of Castile, it was reconstituted as the capital of the Señorío de Sanlúcar, and became during the 15th and 16th centuries one of the most important ports for trade connecting the Atlantic coast with the Mediterranean. After the discovery of the New World, Sanlúcar developed as a port for refitting ships, and was the point of departure for various Spanish conquistadors. On 30 May 1498 Christopher Columbus left for his third voyage from Sanlúcar (See Voyages of Christopher Columbus). Another historical departure was that of Ferdinand Magellan on 10 August 1519, who with a fleet of five ships under his command left Seville and traveled down the Guadalquivir to Sanlúcar de Barrameda at its mouth, where they remained more than five weeks. Sanlúcar also witnessed the arrival in 1522 of the last surviving ship of Magellan's expedition, the 'Nao Victoria commanded by Juan Sebastián Elcano, which was the first ship to circumnavigate the world. Alonso Fernández de Lugo, conqueror of the Canary Islands, of La Palma (1492) and Tenerife (1495), and subsequently the governor of the islands, was born in Sanlúcar. The ill-fated expedition to Florida led by Pánfilo de Narváez left from Sanlúcar on 17 June 1527. Only four members survived including Álvar Núñez Cabeza de Vaca who described the expedition in his work Naufragios.
Many other species worldwide within the family Muricidae, for example Plicopurpura pansa, from the tropical eastern Pacific, and Plicopurpura patula from the Caribbean zone of the western Atlantic, can also produce a similar substance (which turns into an enduring purple dye when exposed to sunlight) and this ability has sometimes also been historically exploited by local inhabitants in the areas where these snails occur. (Some other predatory gastropods, such as some wentletraps in the family Epitoniidae, seem to also produce a similar substance, although this has not been studied or exploited commercially.) The dog whelk Nucella lapillus, from the North Atlantic, can also be used to produce red-purple and violet dyes.
== Contamination in environment == Perchlorates are of concern because of uncertainties about toxicity and health effects at low levels in drinking water, impact on ecosystems, and indirect exposure pathways for humans due to accumulation in vegetables. They are water-soluble, exceedingly mobile in aqueous systems, and can persist for many decades under typical groundwater and surface water conditions.
Noboa was inaugurated for his second term on 24 May 2025. Noboa said in March 2025 that he wanted American, European and Brazilian armies to join his war against criminal gangs. He added he would like President Donald Trump to designate Ecuadorean gangs as terrorist groups, as he has done for some Mexican and Venezuelan cartels. He thereafter started laying the groundwork for U.S. forces to arrive. He met Trump on 30 March 2025, with Trump agreeing to help. On 4 September, Noboa met with US Secretary of State Marco Rubio, who announced the planned expenditure of $20 million USD toward enhanced security cooperation with Ecuador. The United States also designated Los Choneros and Los Lobos as "foreign terrorist organizations." Noboa has cooperated with the US to expand the US military presence in Ecuador, allowing deployments at Manta Air Base, Guayaquil and San Cristóbal, Galapagos Islands under cooperation agreements, rather than bilateral treaties. In September 2025, Noboa's administration terminated a 15-year-old bilateral agreement with Venezuela that had provided a simplified visa and residency process. Noboa has significantly shifted Ecuador's migration policy toward stricter controls, with a particular focus on Venezuelan nationals.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.